Medical technology company Becton Dickinson boosted its yearly earnings projections Thursday, driven by robust sales of medical delivery systems and surgical tools, while also naming Vitor Roque as its permanent chief financial officer.
The company’s stock climbed 3% in early trading after reporting second-quarter financial results that exceeded Wall Street expectations. Becton Dickinson manufactures and distributes medical supplies including needles, syringes and disposal equipment.
The pharmaceutical manufacturing sector appears to be stabilizing for life sciences equipment companies, though they still face challenges from conservative post-pandemic investment in smaller biotech firms and reduced academic research budgets.
Earlier this year, Becton Dickinson finalized the separation and merger of its biosciences and diagnostic solutions division in a $17.5 billion transaction with Waters Corp.
The medical device manufacturer now projects annual adjusted earnings per share will range from $12.52 to $12.72, an increase from its prior guidance of $12.35 to $12.65.
For the quarter ending March 31, the company reported adjusted earnings of $2.90 per share, surpassing analyst predictions of $2.77 according to LSEG data.
The interventional division, which offers surgical solutions, saw revenue grow 7.3%, while the medical essentials unit experienced a 4.7% uptick.
Quarterly revenue reached $4.71 billion, topping the anticipated $4.67 billion. The company maintained its annual sales growth projection in the low single-digit range.
“We would have liked to see more organic earnings upside in the quarter and need to see what drove the stronger other operating income number, but a better top-line performance and Vitor Roque’s formal appointment as CFO still look like small steps in the right direction,” J.P.Morgan analyst Robbie Marcus said.
Roque, who has worked at Becton Dickinson for over 25 years, has been acting as interim CFO since December 2025. In this capacity, he helped execute major initiatives including finalizing the separation of the biosciences and diagnostic solutions business.
